Ardelyx (ARDX) Non Operating Income (2015 - 2026)
Ardelyx's (ARDX) quarterly Non Operating Income came in at $2.1 million in Q1 2026, down 9.2% YoY from $2.3 million in Q1 2025, and up 1.64% on a QoQ basis from $2.1 million in Q4 2025.
Ardelyx (ARDX) Non Operating Income (2015 - 2026) Analysis & Trends
Ardelyx (ARDX) has 12 years of Non Operating Income data on file, last reported at $2.1 million in Q1 2026.
- Quarterly Non Operating Income fell 9.2% year-over-year to $2.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.5 million (down 6.88% YoY) and the FY2025 annual result came in at $8.7 million, down 4.68% from the prior year.
- Non Operating Income climbed to $2.1 million in Q1 2026, from $2.1 million in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $2.4 million in Q3 2025 to a low of $70000.0 in Q2 2022.
- A 5-year average of $1.7 million and a median of $2.1 million in 2025 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2022 — Non Operating Income plunged 91.74% — and 2023, when it surged 2108.57%.
- Tracing ARDX's Non Operating Income over 5 years: stood at $375000.0 in 2022, then jumped by 519.2% to $2.3 million in 2023, then advanced by 3.7% to $2.4 million in 2024, then decreased by 13.7% to $2.1 million in 2025, then increased by 1.64% to $2.1 million in 2026.
- The last three Non Operating Income figures came in at $2.1 million (Q1 2026), $2.1 million (Q4 2025), and $2.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Ardelyx | 1.01 Bn | 729.71 Mn | 115.12 Mn | 2.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.04 Mn |
| Mar 31, 2026 | 2.11 Mn |
| Dec 31, 2025 | 2.08 Mn |
| Sep 30, 2025 | 2.45 Mn |
| Jun 30, 2025 | 1.89 Mn |
| Mar 31, 2025 | 2.33 Mn |
| Dec 31, 2024 | 2.41 Mn |
| Sep 30, 2024 | 2.28 Mn |
| Jun 30, 2024 | 2.15 Mn |
| Mar 31, 2024 | 2.34 Mn |
| Dec 31, 2023 | 2.32 Mn |
| Sep 30, 2023 | 1.46 Mn |
| Jun 30, 2023 | 1.55 Mn |
| Mar 31, 2023 | 1.30 Mn |
| Dec 31, 2022 | 375,000.00 |
| Sep 30, 2022 | 704,000.00 |
| Jun 30, 2022 | 70,000.00 |
| Mar 31, 2022 | 484,000.00 |
| Dec 31, 2021 | 23,000.00 |
| Sep 30, 2021 | -134,000.00 |